BioMarin Pharmaceutical's market cap is currently $12.36B. The company's EPS TTM is $1.66; its P/E ratio is 39.51; BioMarin Pharmaceutical is scheduled to report earnings on February 20, 2025, and the estimated EPS forecast is $0.70. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 2.42B	$ 2.10B	$ 1.85B	$ 1.86B	$ 1.70B
Gross Profit	$ 1.84B	$ 1.61B	$ 1.38B	$ 1.34B	$ 1.34B
Operating Income	$ 194.44M	$ 57.55M	$ -60.01M	$ -96.26M	$ -125.46M
EBITDA	$ 310.28M	$ 267.51M	$ 48.03M	$ -5.85M	$ 33.95M
Net Income	$ 167.65M	$ 141.56M	$ -64.08M	$ 854.03M	$ -23.85M
Balance Sheet
Cash & Short-Term Investments	$ 1.07B	$ 1.29B	$ 1.01B	$ 1.07B	$ 753.81M
Total Assets	$ 6.84B	$ 6.38B	$ 6.00B	$ 5.85B	$ 4.69B
Total Debt	$ 1.10B	$ 1.08B	$ 1.08B	$ 1.08B	$ 848.12M
Net Debt	$ 340.62M	$ 358.49M	$ 491.80M	$ 425.99M	$ 410.67M
Total Liabilities	$ 1.89B	$ 1.77B	$ 1.73B	$ 1.74B	$ 1.57B
Stockholders' Equity	$ 4.95B	$ 4.60B	$ 4.27B	$ 4.11B	$ 3.12B
Cash Flow
Free Cash Flow	$ 51.65M	$ 44.36M	$ 185.31M	$ -52.15M	$ -115.14M
Operating Cash Flow	$ 159.26M	$ 175.90M	$ 304.54M	$ 85.36M	$ 48.26M
Investing Cash Flow	$ -111.24M	$ -20.03M	$ -366.31M	$ -53.62M	$ -31.03M
Financing Cash Flow	$ -18.73M	$ -18.65M	$ -48.00K	$ 181.12M	$ -74.67M

Currency in USD

BioMarin Pharmaceutical Earnings and Revenue History

Income Statement >

BioMarin Pharmaceutical Debt to Assets

Balance Sheet >

BioMarin Pharmaceutical Cash Flow

Cash Flow >

BioMarin Pharmaceutical Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing